Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof
Provided herein are methods of treating solid tumors comprising administering to a subject in need thereof a therapeutically effective amount of the anti-PD-1 antibodies or the antigen-binding fragments thereof described herein.
1 . A method of treating a solid tumor, comprising administering to a subject in need thereof an antibody or antigen binding fragment thereof in a flat dose of 80 mg to 360 mg once every two weeks intravenously, said antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 53; a light chain variable region comprising SEQ ID NO: 67; and a human constant region of IgG4 isotype.
2 . The method of claim 1 , wherein said antibody or antigen binding fragment thereof is administered in a flat dose of 240 mg once every two weeks.
3 . The method of claim 1 , wherein said antibody or antigen binding fragment thereof is administered in a flat dose of 360 mg once every two weeks.
4 . The method of claim 1 , wherein said intravenous administration occurs over a period of 0.1 to 2 hours.
5 . The method of claim 1 , wherein said intravenous administration occurs over a period of 0.1 to 1 hours.
6 . The method of claim 1 , wherein the solid tumor is selected from the group consisting of non-small-cell lung cancer, gastric carcinoma, squamous cell carcinoma of the head and neck, renal cell carcinoma, esophageal cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, and gastroesophageal cancer.
7 . A method of treating a solid tumor, comprising administering to a subject in need thereof an antibody or antigen binding fragment thereof comprising a heavy chain variable region comprising SEQ ID NO: 53; a light chain variable region comprising SEQ ID NO: 67; and a human constant region of IgG4 isotype, wherein said antibody or antigen binding fragment thereof is administered intravenously in a flat dose of 240 mg once every two weeks, 360 mg once every three weeks, or is 480 mg once every four weeks.
8 . The method of claim 7 , wherein said antibody or antigen binding fragment thereof is administered intravenously in a flat dose of 240 mg once every two weeks.
9 . The method of claim 7 , wherein said antibody or antigen binding fragment thereof is administered intravenously in a flat dose of 360 mg once every three weeks.
10 . The method of claim 7 , wherein said antibody or antigen binding fragment thereof is administered intravenously in a flat dose of 480 mg once every four weeks.
11 . The method of claim 7 , wherein said intravenous administration occurs over a period of 0.1 to 2 hours.
12 . The method of claim 7 , wherein said intravenous administration occurs over a period of 0.1 to 1 hours.
13 . The method of claim 7 , wherein the solid tumor is an advanced solid tumor.
14 . The method of claim 7 , wherein the solid tumor is selected from the group consisting of non-small-cell lung cancer, gastric carcinoma, squamous cell carcinoma of the head and neck, renal cell carcinoma, esophageal cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, bladder cancer, ovarian cancer, endometrial cancer, Merkel cell carcinoma, and gastroesophageal cancer.
15 . The method of claim 7 , wherein the solid tumor is non-small cell lung cancer, gastric carcinoma, esophageal cancer, gastroesophageal cancer, or squamous cell carcinoma of the head and neck.
16 . The method of claim 7 , wherein the solid tumor is squamous cell carcinoma of the head and neck or ovarian cancer.
17 . The method of claim 1 , wherein the solid tumor is non-small cell lung cancer, gastric carcinoma, esophageal cancer, gastroesophageal cancer, or squamous cell carcinoma of the head and neck.
18 . The method of claim 1 , wherein the solid tumor is squamous cell carcinoma of the head and neck or ovarian cancer.